You are here

P&T News

August 14

August 10

Letter to health care providers warns of obesity treatment’s potential risks
Fewer patients have access to the lifesaving heart drugs
StimQ Peripheral Nerve Stimulator receives FDA 510(k) clearance

August 8

It may be harder than thought to use “consumerism” to drive down health care costs
Large variations in readings were associated with a higher risk of dementia
The agency is using a wide range of tools to address tobacco use by the young
Five-year grant awarded to Albert Einstein College of Medicine and Montefiore Health System
New formulation eliminates the need for compounding the drug for patients with swallowing difficulties

August 7

Eight-week regimen’s costs estimated at $26,400
ZYN002 fails to meet primary and secondary endpoints
New quotas would be allocated to individual manufacturers
Isomeric Pharmacy Solutions failed repeated FDA inspections

August 3

Treatment combines daunorubicin and cytarabine
Cancer medication becomes first drug with this indication
Other household names are among 17 knocked off the formulary
Drug targets mutations of IDH2 gene identified by new companion diagnostic test
Safety concerns weigh against experimental rheumatoid arthritis drug

August 1

Commission compares the drug crisis to the 9/11 attacks
Problem can be particularly dangerous for women

Pages